Guzmán Valdivia-Gómez G, Soto-Guerrero MT, Flores-Cortés A, Rico-Sierra E, Orozco-López S, Nava-Pineda C, Herrera BA, Cárdenas-Elizondo J, Diarte-Vega H, Armenta-Flores R, Gómez-Bautista FA

Language: Spanish
References: 13
Page: 8-13
PDF size: 65.34 Kb.

ABSTRACT

Introduction: Thromboembolic pulmonary (TEP) secondary to deep venous thrombosis (DVT) of the inferior limbs continues to be a frequently found entity and is fundamentally caused by of the prophylactic measures at-risk patients who had surgery. Material and methods: We have done this multicenter prospective, transversal and descriptive trial in which 96 patients were included who had abdominal surgery and to whom we administered 40 mg of subcutaneous enoxaparine in a single daily dose. Results: Among the most frequent abdominal operations performed were cholecystectomy and appendectomy, 4.5 and 10.4% respectively. All patients presented al least one risk factor and 95% presented one of the following: presence of varicose of the lower limbs; obesity; smoking habit; repeated surgery, or antecedents of acute myocardium infarct. With reference to postoperative bleeding, two patients (2.2%) had a major bleeding during the first 2 days of treatment. Eighteen patients (19.1%) had minor bleeding from day one to day eleven. No significant changes were present in the prothrombin time and partial thromboplastin figures on patients who received treatment, but hemoglobin and hematocrit were signi ficantly lower than in those who received non-steroid anti-inflammatory (p ‹ 0.05) in those who did not receive it (p = 0.1). Two patients had major bleeding (2.2%), and two presented adverse reactions (2.2%), one with pain at application site of low weight heparin and one with pruritus in hands and feet. No patient presented deep venous thrombosis or pulmonary emboli. Discussion: We conclude that utilization of low weight heparin is safe and efficient in prophylaxis of thromboembolic disease in patients who will be operated on and who present a risk factor.

REFERENCES

1. Clagett GP, Anderson FA, Heit H, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108(Suppl):312s.

2. Clagett GP, Anderson FA, Geerts W. Prevention of venous thromboembolism. Chest 1998;114(Suppl):531s-560s.

3. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Intern Angiol 1997;16:3-18.

4. Sigler L, Romero T, Meillón LA, Gutiérrez L, Aguirre GJ, Esparza C. Tromboembolia pulmonar en autopsias en un periodo de 10 años. Rev Med IMSS 1996;34:7-11.

5. Consenso Mexicano sobre enfermedad tromboembólica venosa. Cir Cir 2000;68(Suppl 6):S7-S8.

6. Bratzler DW, Raskob GE, Murria CK. Underuse of venous thromboembolism prophylaxis for general surgery patients. Arch Intern Med 1998;158:1909-12.

7. International Consensus Statement. Prevention of venous thromboembolism guidelines according to scientific evidence. Int Angiol 1997;16:3-38.

8. Bergqvist D. Prolonged prophylaxis against postoperative venous thromboembolism. Haemostasis 1996;26:379-87.

9. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, Landon GC, Jove M. Prolonged and enoxaparine therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001;83:336-45.

10. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K. Subcutaneous enoxaparine once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134:191-202.

11. Labas P, Ohradka B, Vladimir J, Cambal M. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilization and compression. Int Angiol 2000;19:303-7.

12. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997;58:279-85.

13. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis. Drugs 1996;52(Suppl 7):30-7.